KELLEHER FINANCIAL ADVISORS
Position in VRTX — Vertex Pharmaceuticals Inc / Ma
CIK 1507971
NEW YORK, NY
Position in VRTX
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$72,522
+$27,868 QoQ
Shares Held
146
+46.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,503
of 1,735 holders
Holding Since
Sep 2025
4 quarters on record
Common Shares in VRTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026KELLEHER FINANCIAL ADVISORS holds $620,101 across 8 Biotechnology names. VRTX ranks #4 (11.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LENZ |
LENZ Therapeutics, Inc.
|
34,046 | $193,381 | |
| 2 | MRNA |
Moderna, Inc.
|
2,670 | $186,980 | |
| 3 | NWBO |
Northwest Biotherapeutics Inc
|
800,000 | $152,000 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
This page
|
146 | $72,522 | |
| 5 | NKTR |
Nektar Therapeutics
|
150 | $10,471 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
9 | $2,168 | |
| 7 | PBYI |
Puma Biotechnology, Inc.
|
180 | $1,459 | |
| 8 | CRVS |
Corvus Pharmaceuticals, Inc.
|
75 | $1,120 |
All Filings in VRTX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $72,522 | 146 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $44,654 | 100 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $45,336 | 100 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $39,164 | 100 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||